LGALS3 and ovarian cancer: In human ovarian cancer on a chip model, Revacept treatment also inhibited galectin-3-GPVI-mediated platelet-cancer cell interactions and pro-inflammatory phenotype, thereby attenuating the invasive potential of cancer cells (261).